# KLOW peptide references: the cited component literature

> KLOW peptide references — the full cited literature behind every figure on this site, with DOIs and PubMed links for each of the four components.

Every quantitative claim on this site maps to one of these studies. Component research; the blend has none of its own.

## How to read this list

Every numbered citation on this site refers to research on a single KLOW component — GHK-Cu, BPC-157, TB-500/thymosin beta-4, or KPV — or to a regulatory review. None refers to a study of the four-peptide KLOW blend, because no such controlled study exists. The list below carries the full reference for each, with DOI and PubMed or PMC links so you can verify any figure yourself.

## References

[1] Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. https://pubmed.ncbi.nlm.nih.gov/10469335/
[2] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21:976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[3] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
[4] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[5] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[6] Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. https://pubmed.ncbi.nlm.nih.gov/3169264/
[7] Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. https://pubmed.ncbi.nlm.nih.gov/18644225/
[8] Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research. 2011;60(1):79-86. https://pmc.ncbi.nlm.nih.gov/articles/PMC3016279/
[9] Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology. 2016;28(4):438-443. https://pmc.ncbi.nlm.nih.gov/articles/PMC4969472/
[10] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[11] Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11830136/
[12] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[13] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. https://pubmed.ncbi.nlm.nih.gov/20536472/
[14] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[15] Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[16] Getting SJ, Christian HC, Lam CW, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. https://pubmed.ncbi.nlm.nih.gov/12750433/
[17] Sosne G, et al. Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4. Front Immunol. 2024. https://pubmed.ncbi.nlm.nih.gov/39380984/
[18] Wang L, et al. Thymosin beta4 improves the survival of cutaneous flaps of rat and activates Wnt/beta-catenin signaling. Arch Med Sci. 2024. https://doi.org/10.5114/aoms/186188
[19] Zhang Y, et al. Tbeta4-exosome-loaded hemostatic and antibacterial hydrogel to improve vascularized wound repair. Mater Today Bio. 2025. https://doi.org/10.1016/j.mtbio.2025.101585

---

Four peptides, one bloom of cited research — a plain-English field guide to the studies, never a prescription pad.